Acknowledgement
This research was supported by grants of the 'Construction of Scientific Evidence for Herbal Medicine Formulas (K17251)' and 'Construction of Safety and Efficacy for Traditional Herbal Prescriptions of Medicinal Institution (KSN2013310)' projects from the Korea Institute of Oriental Medicine (KIOM), Republic of Korea.
References
- Brasure, M., MacDonald, R., Dahm, P., Olson, C. M., Nelson, V. A., Fink, H. A., et al. (2016). Newer Medications for Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: A Review. Rockville (MD): Agency for Healthcare Research and Quality (US). http://www.ncbi.nlm.nih.gov/books/NBK368444/
- Elkelany, O. O., Owen, R. C., & Kim, E. D. (2015). Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus. Therapeutics and Clinical Risk Management, 11, 507-513. https://doi.org/10.2147/TCRM.S80353
- Azimi, H., Khakshur, A. A., Aghdasi, I., Fallah-Tafti, M., & Abdollahi, M. (2012). A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflammation and Allergy Drug Targets, 11(3), 207-221. https://doi.org/10.2174/187152812800392715
- Yuan, H., Ma, Q., Ye, L., & Piao. G. (2016). The traditional medicine and modern medicine from natural products. Molecules, 21(5): 559. https://doi.org/10.3390/molecules21050559
- Chen, J., Li, P., Sun, Z., Wang, C., Wang, T., & Wang, B. (2015). Five methods of syndrome differentiation and treatment for benign prostatic hyperplasia. Journal of Practical Traditional Chinese Internal Medicine, 29(11), 67-69. https://doi.org/10.13729/j.issn.1671-7813.2015.11.32
- Lee, T. Y. & Chang, H. H. (2010). Longdan Xiegan Tang has immunomodulatory effects on CD4+CD25+ T cells and attenuates pathological signs in MRL/lpr mice. International Journal of Molecular Medicine, 25(5), 677-85. https://doi.org/10.3892/ijmm_00000391
- Kim, J. J., Kim, H. J., An, B. K., Hong, W. S., Kim, W. H., Lee, S. I., et al. (1978). Studies on the therapeutics for liver diseases in herb remedies (VI): Experimental study on the effect on Ryongdamsakan-Tang. Kyung Hee University Oriental Medical Journal, 1, 31-5.
- Seo, M. S., Jin, Y. S., & Jung, K. M. (1991). Effects of Yongdamsagantang and Yongdamsagantang -gamibang on the anti-allergic effect in rats and mice. Journal of Korean Oriental Pediatrics, 5, 15-27. https://www.koreascience.or.kr/article/JAKO199104637300724.pdf
- Furuya, S. & Takahashi, K. (2003). Clinincal investigation of the efficacy of Ryutan-shakan-to in the treatment of postoperative pain and discomfort following transurethral resection of the prostate. Kampo Medicine, 54(1), 183-189. https://www.jstage.jst.go.jp/article/kampomed1982/54/1/54_1_183/_pdf/-char/ja https://doi.org/10.3937/kampomed.54.183
- Moriyama, M. T., Ikeda, R., & Suzuki, K. (2003). Ryutan-shakan-to for the treatment of urination difficulty. Journal of Traditional Medicine, 20(5), 230-234.
- Song, M. K., Park, S. H., Kang, J. S., Ahn, Y. M., Ahn, S. Y., Kim, Y. O., et al. (2010). Report of four cases of Paljung-san on lower urinary tract symptoms in patients with benign prostatic hyperplasia. Journal of Korean Oriental Medicine, 31(1), 153-161. https://www.koreascience.or.kr/article/JAKO201021147394355.pdf
- Lee, S. W., Na, H. Y., Yoo, J. H., Ahn, Y. M., Ahn, S. Y., Kin, Y. O., et al. (2015). Effects of Paljeong-san on chronic nonbacterial prostatitis induced in rats by estradiol. Journal of Internal Korean Medicine, 36(2), 180-188. https://www.koreascience.or.kr/article/JAKO201525850332466.pdf
- Tong, Y. & Zhou, R. Y. (2020). Review of the roles and interaction of androgen and inflammation in benign prostatic hyperplasia. Mediators of Inflammation, 2020:7958316. https://doi.org/10.1155/2020/7958316
- Kruslin, B., Tomas, D., Dzombeta, T., Milkovic-Perisa, M., & Ulamec, M. (2017). Inflammation in prostatic hyperplasia and carcinoma-basic scientific approach. Frontiers in Oncology, 7, 77. https://doi.org/10.3389/fonc.2017.00077
- Park, E., Lee, M. Y., Jeon, W. Y., Lee, N., Seo, C. S., & Shin, H. K. (2016). Inhibitory effect of Yongdamsagan-Tang water extract, a traditional herbal formula, on testosterone -induced benign prostatic hyperplasia in rats. Evidence Based Complement and Alternative Medicine, 2016, 1428923. https://doi.org/10.1155/2016/1428923
- Park, E., Lee, M. Y., Seo, C. S., Jeon, W. Y., & Shin, H. K. (2017). Yongdamsagan-tang, a traditional herbal formula, inhibits cell growth through the suppression of proliferation and inflammation in benign prostatic hyperplasia epithelial-1 cells. Journal of Ethnopharmacology, 209, 230-235. https://doi.org/10.1016/j.jep.2017.08.002
- Park, E., Lee, M. Y., Jeon, W. Y., Seo, C. S., You, S., & Shin, H. K. (2018). Paljung-San, a traditional herbal medicine, attenuates benign prostatic hyperplasia in vitro and in vivo. Journal of Ethnopharmacology, 218, 109-115. https://doi.org/10.1016/j.jep.2018.02.037
- Agbabiaka, T. B., Wider, B., Watson, L. K., & Goodman, C. (2017). Concurrent use of prescription drugs and herbal medicinal products in older adults: A systematic review. Drugs Aging, 34, 891-905. https://doi.org/10.1007/s40266-017-0501-7
- Amitani, M., Amitani, H., Sloan, R. A., Suzuki, H., Sameshima, N., Asakawa, A., et al. (2015). The translational aspect of complementary and alternative medicine for cancer with particular emphasis on Kampo. Frontiers in Pharmacology, 6, 150. https://doi.org/10.3389/fphar.2015.00150
- Vuichoud, C. & Loughlin, K. R. (2015). Benign prostatic hyperplasia: epidemiology, economics and evaluation. The Canadian Journal of Urology, 22(Suppl 1), 1-6. https://www.canjurol.com/html/free-articles/JUV22I5S1F_06_DrLoughlin.pdf
- Olesovsky, C. & Kapoor, A. (2016). Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. Therapeutic Advances in Urology, 8(4), 257-271. https://doi.org/10.1177/1756287216650132
- Kim, E. H., Larson, J. A., & Andriole, G. L. (2016). Management of Benign Prostatic Hyperplasia. Annual Review of Medicine, 67, 137-151. https://doi.org/10.1146/annurev-med-063014-123902
- Di Silverio, F., Bosman, C., Salvatori, M., Albanesi, L., Proietti Pannunzi, L., Ciccariello, M., et al. (2005). Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). European Urology, 47(1), 72-79. https://doi.org/10.1016/j.eururo.2004.08.024
- Kramer, G., Mitteregger, D., & Marberger, M. (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? European Urology, 51(5), 1202-1216. https://doi.org/10.1016/j.eururo.2006.12.011
- Ma, C. H., Lin, W. L., Lui, S. L., Cai, X. Y., Wong, V. T., Ziea, E., et al. (2013). Efficacy and safety of Chinese herbal medicine for benign prostatic hyperplasia: systemic review of randomized controlled trials. Asian Journal of Andrology, 15(4), 471-482. https://doi.org/10.1038/aja.2012.173
- Lim, J. H., Lee, J. R., Kim, S. C., & Jee, S. Y. (2007). Inhibitory effect of Yongdamsagantang water extract in IL-6 and nitric oxide production in lipopolysaccharide-activated RAW264.7 cells. Oriental Pharmacy and Experimental Medicine, 7(3), 321-329. https://doi.org/10.3742/OPEM.2007.7.3.321
- Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T.C., et al. (2004). Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metabolism and Disposition, 32(11), 1201-1208. https://doi.org/10.1124/dmd.104.000794
- Huang, S. M. & Lesko, L.J. (2004). Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned? Journal of Clinical Pharmacology, 44(6), 559-569. https://doi.org/10.1177/0091270004265367
- Prueksaritanont, T., Chu, X., Gibson, C., Cui, D., Yee, K. L., Ballard, J., et al. (2013). Drug-drug interaction studies: regulatory guidance and an industry perspective. The AAPS Journal, 15(3), 629-645. https://doi.org/10.1208/s12248-013-9470-x
- Grimstein, M. & Huang, S.M. (2018). A regulatory science viewpoint on botanical-drug interactions. Journal of Food and Drug Analysis, 26(2S), S12-S25. https://doi.org/10.1016/j.jfda.2018.01.013
- Hulin-Curtis, S. L., Petit, D., Figg, W. D., Hsing, A. W., & Reichardt, J. K. (2010). Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncology, 6(12), 1897-1913. https://doi.org/10.2217/fon.10.149